The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Peroxisome proliferator‐activated receptors in the cardiovascular system
Open accessAbstract
Peroxisome proliferator‐activated receptor (PPAR)s are a family of three nuclear hormone receptors, PPARα, ‐δ, and ‐γ, which are members of the steriod receptor superfamily. The first member of the family (PPARα) was originally discovered as the mediator by which a number of xenobiotic drugs cause peroxisome proliferation in the liver. Defined functions for all these receptors, until recently, mainly concerned their ability to regulate energy balance, with PPARα being involved in β‐oxidation pathways, and PPARγ in the differentiation of adipocytes. Little is known about the functions of PPARδ, though it is the most ubiquitously expressed. Since their discovery, PPARs have been shown to be expressed in monocytes/macrophages, the heart, vascular smooth muscle cells, endothelial cells, and in atherosclerotic lesions. Furthermore, PPARs can be activated by a vast number of compounds including synthetic drugs, of the clofibrate, and anti‐diabetic thiazoldinedione classes, polyunsaturated fatty acids, and a number of eicosanoids, including prostaglandins, lipoxygenase products, and oxidized low density lipoprotein. This review will aim to introduce the field of PPAR nuclear hormone receptors, and discuss the discovery and actions of PPARs in the cardiovascular system, as well as the source of potential ligands. British Journal of Pharmacology (2000) 129, 823–834; doi:10.1038/sj.bjp.0703149
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 5×
“Since the original discovery of PPARa from mouse liver (Issemann & Green, 1990), as a nuclear receptor that responded to peroxisome proliferators such as WY-14,643, nafenopin, and clo®bric acid, the related family members, PPARd (PPARb; Dreyer et al., 1992), and PPARg (Dreyer et al., 1992) were…”
BackgroundInfluentialThe RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889 · cited 1×
“RXR also exists in multiple isoforms, RXRa, -b, and -g (see Chambon, 1996), and like PPARs have a di erent tissue distribution (see Table 2; Mangelsdorf et al., 1992).”
Background15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272 · cited 5×
“British Journal of Pharmacology (2000) 129, 823 ± 834 Keywords: PPAR; macrophage; endothelial cells; vascular smooth muscle; angiogenesis; atherosclerosis Abbreviations: COX-1, constitutive COX; COX-2, inducible COX; 15d-PGJ2, 15-deoxy-D12,14-PGJ2; ETYA, eicosatetraynoic acid; HETE, hydroxyeicosatetaenoic acid; HODE,…”
InfluentialBraissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Cited by
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 545
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
O'Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 510
Anti-Inflammatory Mechanisms in the Vascular Wall
Tedgui, A., & Mallat, Z. (2001) · Circulation Research · doi:10.1161/hh0901.090440 · Cited by 422
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Self-citationPeroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 369
WAYMAN, N. S., HATTORI, Y., MCDONALD, M. C., MOTA‐FILIPE, H., CUZZOCREA, S., PISANO, B., CHATTERJEE, P. K., & THIEMERMANN, C. (2002) · The FASEB Journal · doi:10.1096/fj.01-0793com · Cited by 361
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado-Lopez, F., & Moore-Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 354
Osorio, J. C., Stanley, W. C., Linke, A., Castellari, M., Diep, Q. N., Panchal, A. R., Hintze, T. H., Lopaschuk, G. D., & Recchia, F. A. (2002) · Circulation · doi:10.1161/01.cir.0000023531.22727.c1 · Cited by 332
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 317
Yue, T.-L., Chen, J., Bao, W., Narayanan, P. K., Bril, A., Jiang, W., Lysko, P. G., Gu, J.-L., Boyce, R., Zimmerman, D. M., et al. (2001) · Circulation · doi:10.1161/hc4601.099403 · Cited by 295
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
Bordet, R., Ouk, T., Petrault, O., Gelé, P., Gautier, S., Laprais, M., Deplanque, D., Duriez, P., Staels, B., Fruchart, J. C., et al. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341341 · Cited by 273
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
Carley, A. N., Semeniuk, L. M., Shimoni, Y., Aasum, E., Larsen, T. S., Berger, J. P., & Severson, D. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2003 · Cited by 94
Metadata
- Authors
- Bishop‐Bailey, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-03
- Volume
- 129
- Issue
- 5
- Pages
- 823-834
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2065133286
- Cited by
- 363
- References
- 101
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.